Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Successful large biotechs such as Vertex and Regeneron have powerful ... and has already parted ways with BeiGene on PD-1 and TIGIT checkpoint inhibitors. AZ, Lilly and J&J would appear to be ...

The stock market showed resilience after Monday's DeepSeek-spurred sell-off in AI hardware stocks. Apple, Tesla, Microsoft led big earnings.

This was followed by Merck & Co’s Keytruda (pembrolizumab) and a gang of rival PD-L/PD-L1 checkpoint inhibitors ... And firms such as Vertex have added to the controversy with tough pricing ...

Jan 30 (Reuters) - The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' (VRTX.O), opens new tab drug to treat acute pain, the health regulator said on Thursday, offering a ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

BOSTON, January 12, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the ...

Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

Get the Real Story Behind Every Major Earnings Report RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

Vertex has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past, it’s that there are many kinds of pain.

WASHINGTON, Jan 30 (Reuters) - A small U.S. security firm is hiring nearly 100 U.S. special forces veterans to help run a checkpoint in Gaza during the Israel-Hamas truce, according to a company ...

We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...